Xinhuan Biotech's 3D Cell Manufacturing Platform Enables Dabio's Stem Cell Drug to Receive IND Approval for Type 2 Diabetes

Guangzhou Dabo Biological Products Co., Ltd. is an innovative drug research and development enterprise in China with a rich pipeline of drugs and independent innovation capabilities in the field of precision-targeted anti-tumor drugs. As a national high-tech enterprise and a specialized and new enterprise in Guangdong Province, it is committed to independent research and development, clinical research, and commercial production. Long-term relentless efforts have enabled Dabo Bio to continuously achieve impressive results in the field of anti-tumor drug research and development.

The company has always focused on forward-looking technology research and development. It has built two provincial enterprise key laboratories (engineering laboratories) for anti-tumor drug research and development and one municipal enterprise key laboratory for gene therapy. Additionally, it has established five new drug research and development functional platforms.

The company has established an oncology drug development pipeline and a GMP production platform in compliance with international standards. Its mastery of cutting-edge core technologies has enabled the company to continuously develop new drugs. After more than 20 years of relentless efforts, while making in-depth vertical progress, the company also places equal importance on horizontal expansion. It explores not only in the field of genetic engineering but also in cell-based (including immune and regenerative cells) and protein-related biologics, forming a sustainable series of product lines.

Beijing Huakan Biotechnology Co., Ltd. was established in 2018, led by Professor Yanan Du's research team from Tsinghua University School of Medicine, with participation and co-construction by Tsinghua University. The core technology originates from the transformation of scientific and technological achievements at Tsinghua University, and with this technology, the company has been honored on the "Pilot Technology List" of the China Association for Science and Technology's "Innovation in China." As a national high-tech enterprise, a national specialized and sophisticated "Little Giant" enterprise, and a potential unicorn company, it has received support from multiple key R&D projects by the Ministry of Science and Technology of China.

As a high-quality 3D cell manufacturing expert, CytoNiche provides a one-stop customized solution for large-scale cell expansion based on 3D microcarriers, creating an original 3D cell intelligent manufacturing platform. This achieves large-scale, automated, intelligent, and closed production of cell drugs and their derivatives, helping global customers establish the most advanced cell drug production lines. After pioneering a [billion-level] stem cell preparation process pipeline, it accelerates towards a [trillion-level], committed to empowering the cell and gene therapy industry with 3D cell large-scale intelligent manufacturing technology, benefiting more patients.